SCHEMBL3467976

SCHEMBL3467976

O=C(CBr)c1c(F)cccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
GAA P10253 8/20 0.50
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
HPGD P15428 1/20 0.46
ALDH1A1 P00352 1/20 0.45
ITGB2 P05107 1/20 0.44
ICAM1 P05362 1/20 0.44
ITGAL P20701 1/20 0.44
FEN1 P39748 1/20 0.44
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30016040 1.00 KMT2A (0.56) KMT2AMEN1GAACES2CES1
SCHEMBL169401 0.86 FEN1 (0.57) KMT2AMEN1JAK2JAK1TYK2
SCHEMBL1278384 0.86 CES2 (0.56) KMT2AMEN1CES2CES1ALDH1A1
SCHEMBL6462215 0.81 MEN1 (0.56) KMT2AMEN1GAACES2CES1
SCHEMBL31298356 0.79 CES2 (0.48) KMT2AMEN1CES2CES1HPGD
SCHEMBL4737286 0.79 CES2 (0.48) KMT2AMEN1CES2CES1HPGD
SCHEMBL2876974 0.78 GAA (0.58) KMT2AMEN1GAACES2CES1
SCHEMBL16563485 0.77 KMT2A (0.52) KMT2AMEN1GAACES2CES1
SCHEMBL9526409 0.77 TYK2 (0.50) KMT2AMEN1TYK2HPGDALDH1A1
SCHEMBL29932768 0.77 TYK2 (0.50) KMT2AMEN1TYK2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 US disclosed
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2024-08-29 US disclosed
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-02-13 US disclosed
EP-4069696-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-10-12 EP disclosed
WO-2021113479-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-06-10 WO disclosed
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-06-10 US disclosed
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US disclosed
EP-3033342-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2016-06-22 EP disclosed
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS GRUENENTHAL GMBH (DE) 2016-06-02 US disclosed
WO-2015022073-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2015-02-19 WO disclosed
WO-2013050270-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-04-11 WO disclosed
WO-2010074746-A1 METHODS OF USE FOR OPSIN BINDING LIGANDS BIKAM PHARMACEUTICALS, INC. (US) 2010-07-01 WO disclosed
EP-1594866-A1 ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES PFIZER INC. (US) 2005-11-16 EP disclosed
EP-1438046-A4 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMA (US) 2004-10-20 EP disclosed
US-20040176431-A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use PFIZER, INC. 2004-09-09 US disclosed
WO-2004072070-A1 ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES PFIZER INC. (US) 2004-08-26 WO disclosed
EP-1438046-A2 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2004-07-21 EP disclosed
US-6720346-B2 (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS AGOURON PHARMACEUTICALS, INC. 2004-04-13 US disclosed
US-20030225147-A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use AGOURON PHARMACEUTICALS INC. 2003-12-04 US disclosed
WO-2003004467-A2 THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS NOX1, CYBB, NOX4 KMT2A 3820/4885MEN1 4712/4885GAA 335/4885
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 KMT2A 1324/4885MEN1 3840/4885GAA 426/4885
US-20030225147-A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use TK1, MKI67, CDKN1A KMT2A 1184/4885MEN1 812/4885GAA 1088/4885
US-20160151337-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS AADAC, PRRC2C, PRRC2A KMT2A 4296/4885MEN1 3713/4885GAA 2738/4885
US-20240287086-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 KMT2A 1324/4885MEN1 3840/4885GAA 426/4885
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR3, FGFR1, FGFR2 KMT2A 1324/4885MEN1 3840/4885GAA 426/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 KMT2A 2514/4885MEN1 4565/4885GAA 2760/4885
US-20040176431-A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use MKI67, TK1, CDK2 KMT2A 1183/4885MEN1 2650/4885GAA 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.